Physician profile
Robert A Linden
NPI 1932317633
$13,521.64
in general payments reported to CMS, 2019-2025
31 companies · $9,406 in 2025
The $9,406 reported for 2025 was more than what 94% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $132 · 2021: $766 · 2022: $255 · 2023: $271 · 2024: $2,152 · 2025: $9,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,450 · Food and Beverage: $2,159 · Travel and Lodging: $1,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,450.00 |
| Food and Beverage | $2,159.04 |
| Travel and Lodging | $1,219.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calyxo, INC. | $10,769.69 | 2022-2025 | Cvac Aspiration System |
| Teleflex LLC | $550.02 | 2021-2025 | Urolift, Deknatel |
| Astellas Pharma US INC | $294.11 | 2019-2022 | |
| Procept Biorobotics Corporation | $249.76 | 2023-2024 | Aquabeam Robotic System, Aquabeam System |
| Boston Scientific Corporation | $221.07 | 2019-2024 | Lithovue |
| Stryker Corporation | $220.51 | 2023-2025 | 1788, Stryker |
| Abbvie INC. | $179.45 | 2021-2025 | |
| Neotract INC. | $178.45 | 2019 | |
| Medtronic, INC. | $102.36 | 2021-2023 | Interstim |
| Bayer Healthcare Pharmaceuticals INC. | $89.39 | 2020-2021 | |
| Janssen Biotech, INC. | $73.35 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $53.46 | 2025 | Gemtesa |
| Endo Pharmaceuticals INC. | $49.86 | 2019-2021 | |
| Civco Medical Instruments | $49.10 | 2025 | |
| Bluewind Medical | $46.38 | 2024 | Revi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $45.34 | 2019-2025 | Xyosted |
| 180 Medical, INC. | $41.24 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $34.98 | 2025 | Erleada |
| Axonics, INC. | $34.75 | 2021 | |
| Dentsply Ih Ab | $30.65 | 2021-2023 | Lofric |
| Urogen Pharma, INC. | $30.31 | 2025 | |
| Clarus Therapeutics INC. | $26.00 | 2021 | |
| Coloplast Corp | $24.91 | 2021 | |
| Verity Pharmaceuticals INC. | $23.53 | 2025 | Trelstar |
| Mission Pharmacal Company | $17.48 | 2021 | |
| Merck Sharp & Dohme LLC | $14.93 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $14.86 | 2020 | |
| Therapeuticsmd, INC. | $14.22 | 2019 | |
| Pfizer INC. | $13.94 | 2021 | |
| Urovant Sciences INC | $13.94 | 2021 | |
| Acerus Pharmaceuticals Corporation | $13.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Linden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.